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Abstract
Mechanical ventilation is the standard life-support technique for patients with
severe acute respiratory failure. However, some patients develop persistent
and refractory hypoxemia because their lungs are so severely damaged that
they are unable to respond to the application of high inspired oxygen
concentration and high levels of positive end-expiratory pressure. In this article,
we review current knowledge on managing persistent hypoxemia in patients
with injured lungs.
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Introduction and context
Acute hypoxemic respiratory failure due to acute respiratory 
distress syndrome (ARDS) is one of the most severe forms of acute 
lung injury. Caused by direct (pulmonary) or indirect (systemic) 
insults to the lungs, it is characterized clinically by hypoxemia 
that does not respond to the administration of high inspiratory 
concentrations of oxygen (FiO2) and by the presence of bilateral 
pulmonary infiltrates on chest imaging due to high-permeability 
pulmonary edema1. There is no specific pharmacologic treatment 
for ARDS. An integral part of the supportive therapy of patients 
with ARDS is the application of invasive mechanical ventilation 
(MV). The goal of MV is to achieve adequate gas exchange and 
tissue oxygenation without further damaging the lungs. Since 
the first description of ARDS2, the use of positive end-expiratory 
pressure (PEEP) has been adopted as standard practice for the 
ventilator management of acute respiratory failure. PEEP prevents 
end-expiratory alveolar collapse.
Most patients with ARDS improve their oxygenation—as 
assessed by the arterial partial pressure of oxygen/FiO2 (PaO2/
FiO2) ratio—after 24 hours of routine intensive care manage-
ment and after the application of moderate to high levels of 
PEEP. Today, refractory hypoxemia (which, in most reports, has 
been defined as having a PaO2 of less than 60 mm Hg on a FiO2 
of 0.8–1.0 and PEEP of more than 10 cm H2O for more than 
12–24 hours) is an infrequent cause of death3. There are no data 
that link a particular baseline PaO2/FiO2 to predictable struc-
tural changes in the alveolar-capillary membrane at the time of 
ARDS diagnosis. However, there is recent evidence showing a 
correlation between lung injury severity and outcome when the 
PaO2/FiO2 ratio is assessed under standard ventilatory settings at 
24 hours of ARDS onset4. Therefore, in this context, although there 
is no standard definition for persistent hypoxemia in terms of a 
predetermined PaO2 value under a specific FiO2 and PEEP for a 
specific period of time, for the purpose of this review persistent 
hypoxemia exists when the PaO2/FiO2 is not more than 200 mm Hg 
after 24 hours of MV. The aim of this review is to summarize 
the current knowledge on a number of techniques that have been 
shown to improve oxygenation and outcome in ARDS patients 
with persistent hypoxemia.
Muscle paralysis during lung-protective ventilation
There is unequivocal evidence that MV can cause or aggravate 
lung damage—a concept termed ventilator-induced lung injury 
(VILI). Many of the pathophysiological consequences of VILI 
resemble those of ARDS5. Since the publication of the land-
mark paper by the ARDS Network (ARDSnet) in 20006 and the 
pooled data in a meta-analysis of six randomized controlled trials 
(RCTs) comparing different strategies to apply PEEP7, current 
recommendations for ventilating patients with ARDS include the 
application of low tidal volumes (VTs) (4–8 mL/kg predicted 
body weight, or PBW), PEEP levels that maintain a positive end- 
expiratory transpulmonary pressure, limiting plateau pressure to 
less than 30 cm H2O, limiting driving pressure (plateau pressure 
minus PEEP) to less than 15 cm H2O, and limiting FiO2 to main-
tain a PaO2 of 55 to 80 mm Hg or a peripheral capillary oxygen 
saturation (SpO2) of 90% to 95%. These five elements are the main 
components of the framework for “lung-protective ventilation”.
However, despite the use of volume- and pressure-limited venti-
latory strategies, mechanically ventilated patients with ARDS can 
be exposed to tidal hyperinflation during spontaneous inspiratory 
and expiratory efforts, especially in the early stages of ARDS. 
VT set by clinicians does not always correspond to the true VT 
delivered, because of double triggering, reverse triggering, and 
pendelluft, which can occur despite the use of analgesics and 
sedatives. Papazian et al.8 examined the hypothesis that remov-
ing spontaneous respiratory efforts in ARDS patients with per-
sistent hypoxemia would improve lung mechanics and decrease 
oxygen consumption. The authors performed an RCT—the ARDS 
et Curarisation Systematique (ACURASYS) study—in 340 ARDS 
patients with a PaO2/FiO2 of less than 150, a PEEP of at least 
5 cm H2O, and VT between 6 and 8 mL/kg PBW enrolled 
within the first 48 hours of ARDS onset. Patients were randomly 
assigned to receive either a neuromuscular blockade (NMB) agent 
(cisatracurium) or placebo for 48 hours. The group of patients 
receiving muscle paralysis had lower adjusted 90-day mortal-
ity (primary outcome) and higher ventilator-free days (VFDs) at 
28 days than the placebo group. The prevalence of neuromuscu-
lar weakness did not differ between groups. It is well known that 
NMB minimizes work of breathing and patient-ventilator asyn-
chronies in patients with ARDS9. However, the results of the 
ACURASYS study, seven years after its publication, remain 
controversial. The major criticisms of this trial include a lack of 
measurement of ventilator asynchrony in the control group, the 
Kaplan-Meier survival curves separated only after day 14, and, 
most importantly, the primary end-point of the trial, adjustment 
of 90-day mortality, achieved statistical significance only with 
acuity adjustment10. In a recent publication11, the same group of 
investigators examined the effects of NMB on transpulmonary 
pressure in a small pilot RCT of 24 patients with persistent ARDS 
and found that NMB could exert beneficial effects in patients with 
moderate ARDS by limiting expiratory efforts. Although these 
early data are supportive of the use of NMB, additional verifica-
tion of early NMB in ARDS is required if widespread implemen-
tation is to occur. A new RCT is currently enrolling patients with 
moderate to severe ARDS and is powered for validating and 
assessing the efficacy and safety of early NMB in reducing mor-
bidity and 90-day mortality12. This trial is not an exact replication 
of ACURASYS since both groups of patients will receive a high 
PEEP open-lung ventilation approach. If the trial yields a positive 
result, it will establish early NMB as a standard approach in the 
management of patients with moderate to severe ARDS.
Prone ventilation
ARDS is a histopathologically heterogeneous disease process13. 
Recruitability of alveolar space with PEEP is also heterogeneous 
both between patients and within the lungs. Changes in posture 
can have profound effects on the pulmonary function of critically 
ill patients. Therapeutic alteration in the distribution of deliv-
ered gas for mitigating VILI is the basis of both prone ventila-
tion and recruitment maneuvers (RMs). Prone positioning should 
be viewed as an adjunctive therapy to be used in combination 
with other accepted therapies in the management of critically ill 
patients with persistent hypoxemia. However, although it is widely 
known to improve oxygenation in patients with ARDS and shown 
to aid in alveolar recruitment, controversy over its use in clinical 
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practice continues. Ventilating an ARDS patient in a prone posi-
tion provides several physiological advantages for the manage-
ment of persistent hypoxemia, including an increase in functional 
residual capacity, a change in regional diaphragm motion, better 
matching of ventilation to perfusion, removal of the heart’s weight 
from the lung, and improved secretion clearance14. In general, 
prone ventilation can be performed safely if health-care staff are 
appropriately trained. Although there are sufficient data to 
conclude that oxygenation frequently improves when patients 
with ARDS are turned prone, several studies on prone ventilation 
produced conflicting results about its efficacy in persistent hypox-
emia, until a meta-analysis suggested benefits specifically in the 
most hypoxemic patients receiving lung-protective MV15. As with 
NMB, there is only one large positive RCT demonstrating survival 
benefit16 of prone ventilation in moderate to severe ARDS, the 
“Proning Severe ARDS Patients” (PROSEVA) trial17. The inves-
tigators randomly assigned 466 patients with persistent ARDS 
(as defined by a PaO2/FiO2 of less than 150 mm Hg with FiO2 of 
less than 0.6 and PEEP of at least 5 cm H2O) to undergo prone-
positioning sessions of at least 16 hours or to be left in the supine 
position. In both groups, patients were ventilated using the low 
PEEP-FiO2 table from the ARDSnet trial6. The 28-day mortal-
ity rates were 32.8% in the supine group and 16.0% in the prone 
group (P <0.001), a difference that persisted at 90 days after 
random assignment (41.0% in the supine group versus 23.6% in the 
prone group, P <0.001).
Proponents of prone ventilation (which usually also requires 
NMB) suggest that the approach taken in PROSEVA was a 
refinement of a technique that finally got it right when patients 
were ventilated with a VT of not more than 8 mL/kg PBW18. 
Detractors suggest that the large treatment effect seen (almost an 
absolute 20% difference) was too good to be true16,19. Of note, 
patients assigned to the supine position were ventilated during 
the first three days with very low PEEP levels (mean of 9 ± 3 cm 
H2O) for patients with severe ARDS. An additional, large vali-
dation RCT is required to confirm these findings if widespread 
implementation of prone ventilation in early stages of persistent 
ARDS is to occur. However, such a trial should ensure that the 
control arm receives a high PEEP open-lung ventilation approach.
Driving pressure
Recently, attention regarding VILI has focused on driving pres-
sure (plateau pressure minus PEEP). Amato et al.20, in an 
analysis of nine pre-existing RCTs, determined that driving 
pressure had a greater impact on mortality in persistent ARDS 
than VT, plateau pressure, or PEEP. They identified a cut-point of 
15 cm H2O. That is, the risk of death increased as driving pres-
sure exceeded 15 cm H2O. Subsequently, Villar et al.21, in a re- 
analysis of data from three epidemiologic studies in ARDS 
where all patients were ventilated with a lung-protective strat-
egy, determined that driving pressure and plateau pressure had 
essentially the same impact on mortality with a driving pressure 
cut-point of 18 cm H2O. In addition, Chiumello et al.22 identi-
fied a strong correlation between airway driving pressure and 
transpulmonary driving pressure (calculated as end-inspiratory 
transpulmonary pressure minus end-expiratory transpulmonary 
pressure). It seems physiologically sound to be concerned with 
driving pressure. The exact cut-point is still open to debate but all 
would agree that the lower the driving pressure the better the patient 
outcome.
FiO2
Oxygen is routinely administered to almost all critically ill 
patients. Although oxygen therapy can be lifesaving, it is not with-
out serious effects. Too little oxygen is problematic but so is too 
much23. Rachmale et al.24 assessed the effects of excessive oxy-
gen exposure (defined as FiO2 of more than 0.5 despite SpO2 of 
more than 92%) in 210 mechanically ventilated ARDS patients on 
pulmonary outcomes. The authors found that prolonged exposure 
to excessive oxygen was associated with worsening lung func-
tion (worse oxygenation index and more days on MV), longer 
intensive care unit (ICU) stay, and longer hospital stay. In a 
subsequent RCT, Girardis et al.25 randomly assigned mechani-
cally ventilated medical/surgical patients to receive conservative 
oxygen therapy (target PaO2 of 70 to 100 mm Hg and SpO2 of 
94% to 98%) or standard oxygen therapy (target PaO2 of up to 
150 mm Hg and SpO2 of 97% to 100%). All other variables 
associated with care were standardized across groups. They 
found a significant difference in ICU mortality (11.6% con-
servative versus 20.2% standard), hospital and 60-day mortality, 
favoring conservative oxygen therapy. Thus, it is in the patients’ 
best interest to maintain the PaO2 of 55 to 80 mm Hg and SpO2 
of 90% to 95% as defined by the ARDSnet protocol6 to eliminate 
the effect of oxygenation status on outcome. Additional validation 
studies are in the process of being published.
Recruitment maneuvers and transpulmonary 
pressure
Imaging studies have provided insight into the ARDS lung26. 
Classic computed tomography (CT) has shown that some lung 
regions in ARDS appear radiographically to be relatively nor-
mal but that some other areas are partially collapsed and unable 
to participate in gas exchange. The concept of the “baby lung” 
has led to the understanding of potential interaction of MV set-
tings and patient outcome and often using CT as a reference for 
applying personalized ventilatory management in patients with 
severe ARDS27. Collapsed or atelectatic areas of the lung can be 
re-expanded by the application of brief periods of sustained 
high-inflation pressure followed by the application of adequate 
levels of PEEP to maintain the new re-aerated region open28. 
These RMs are intended to re-open collapsed alveoli and to attenu-
ate the injurious effects of the repetitive opening and closing of 
alveolar units, promoting lung protection by reducing lung stress 
in areas of heterogeneity. Three commonly used RMs are sighs, 
sustained inflations, and extended sighs29. PEEP prevents lung 
unit collapse at end expiration. Much controversy exists over 
the benefits of RMs in persistent ARDS. A systematic review of 
40 studies30 showed that RMs increased oxygenation and improved 
respiratory system mechanics, but little information about 
the long-term effects and usefulness of these interventions was 
available until recently. The major differences seem to be based on 
the selection of PEEP post-RM that sustains the benefit of RMs.
In a pilot RCT that was performed from 2007 to 2013 in 200 
ARDS patients with persistent hypoxemia and that compared the 
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ARDSnet protocol6 using low levels of PEEP with an open-lung 
approach—which involves RMs and a decremental PEEP trial for 
identifying the PEEP level associated with maximum dynamic 
compliance—Kacmarek et al.31 found that the open-lung approach 
ventilatory strategy improved oxygenation and respiratory sys-
tem mechanics without detrimental effects on 60-day mortality 
(33% in the ARDSnet group versus 29% in the open-lung 
approach), VFDs, or barotrauma. This trial supported the need for a 
large RCT using RMs in association with PEEP titrated by com-
pliance of the respiratory system to test whether this approach 
is able to increase survival in patients with persistent ARDS. Such a 
trial has been finalized recently and we await its results32.
A more recent approach for titrating PEEP is to optimize the 
end-expiratory transpulmonary pressure (PEEP minus pleural 
pressure). Pleural pressure, estimated via esophageal manom-
etry, has been shown to differ considerably among patients with 
acute respiratory failure, indicating that lung and chest wall 
mechanics both contribute substantially and unpredictably to res-
piratory system mechanics and airway pressures measured by the 
ventilator33. During RM and PEEP, the distending pressure 
delivered by the ventilator consists of two components: one to 
inflate the lung and one to expand the chest wall. Accordingly, 
RM and PEEP can be titrated safely to an optimal transpulmonary 
pressure target. In a small pilot RCT of 61 ARDS patients with 
persistent hypoxemia, in which the use of ARDSnet PEEP-FiO2 
table was compared with an open-lung approach that included 
esophageal pressure–guided setting of PEEP (EPVent trial), 
targeting a positive end-expiratory transpulmonary pressure 
(PEEP minus esophageal pressure) showed that esophageal-
guided PEEP was associated with improved oxygenation and, after 
adjusting for illness severity, improved survival34. A multicenter 
validation trial powered (estimated sample size of 200 patients 
with ARDS) for patient-centered outcome (a composite outcome of 
mortality and VFDs at 28 days) is ongoing35.
Of note, esophageal pressure–guided MV translated into higher 
PEEP application (18 versus 12 cm H2O on day 1), demonstrating 
that commonly used PEEP levels by clinicians are inade-
quate for optimal MV in patients with ARDS. In a small non- 
randomized interventional study in 14 critically ill, mechanically 
ventilated, morbidly obese patients, Pirrone et al.36 evaluated both 
methods of titrating PEEP (that is, RM followed by a decremen-
tal PEEP trial versus RM followed by targeting a positive end- 
expiratory transpulmonary pressure) and observed that the two 
methods of determining optimal PEEP identified similar PEEP 
levels (20.7 ± 4.0 versus 21.3 ± 3.8 cm H2O) but that the PEEP 
levels set by the clinicians (11.6 ± 2.9 cm H2O) were associated 
with lower lung volumes, worse elastic properties of the lung, and 
lower oxygenation.
Extracorporeal membrane oxygenation
This technique was originally applied to patients with severe acute 
respiratory failure in which it was impossible to provide adequate 
oxygenation by MV37. Since MV is reliant on functional lung 
units for gas diffusion, it would be unable to provide respiratory 
support when there is no minimum amount of functional alveoli. 
Substituting alveolar gas exchange by extracorporeal membrane 
oxygenation (ECMO) or extracorporeal carbon dioxide (CO2) 
removal would allow a marked reduction of VT, respiratory rate, 
and FiO2, reducing the risk of VILI. To provide gas exchange 
during ECMO, a portion of the cardiac output must go through the 
ECMO circuit via the femoral, saphenous, or jugular veins. During 
ECMO, CO2 is removed by the extracorporeal circuit with MV 
maintained at low ventilatory rates, high PEEP levels, and with 
VT to maintain a plateau pressure below 29 cm H2O. In the last 
few years, there have been considerable advances in extracorporeal 
life support, and despite widespread and growing use worldwide in 
patients with ARDS38, at present the evidence base for ECMO in 
ARDS is scarce, consisting of case series, observational cohorts, 
and only one RCT.
A recent RCT, referred to as the CESAR (Conventional ventila-
tory support versus Extracorporeal membrane oxygenation for 
Severe Adult Respiratory failure) trial, assessed the effectiveness 
of ECMO in 180 patients with severe ARDS39. However, rather 
than directly assessing ECMO in refractory hypoxemia, investiga-
tors compared ECMO management at a referring center with MV 
management at tertiary centers. The 6-month survival rate was 
higher in patients at the ECMO center than in those patients man-
aged with MV at participating centers (63% versus 47%, P = 0.03). 
Major concerns with the reported results included (i) patients 
allocated to MV were treated with conventional MV or with 
high-frequency ventilation, (ii) 30% of patients in the control 
group were not ventilated with a lung-protective strategy, (iii) the 
ECMO center did not treat patients randomly assigned to the 
conventional management group, (iv) no data regarding ventila-
tion at study entry and during the MV period were presented, and 
(v) many patients randomly assigned to ECMO never received 
ECMO. A multicenter trial for severe ARDS comparing ECMO 
with a protocolized lung-protective MV strategy is ongoing40.
There are some studies suggesting the combined use of ECMO 
with prone positioning in severe ARDS. Guervilly et al.41 reported 
their experience in 15 patients with severe ARDS who were 
turned to a prone position during ECMO therapy because of at 
least one of the three following conditions: PaO2/FiO2 of less than 
70 on maximal oxygenation, plateau pressure of more than 32 cm 
H2O, or failure to wean ECMO after at least 10 days on ECMO 
support. The authors found significant improvement in oxy-
genation and no complications related to proning. Also, Kredel 
et al.42 reported their experience of positional therapy in a 
retrospective cohort of nine patients with severe ARDS treated 
with ECMO. Positioning therapy included complete prone, par-
tially prone, and continuous lateral rotational therapy. During 
the first three days, the oxygenation index and lung compliance 
improved significantly, suggesting that positioning therapy can be 
performed safely in patients with ARDS treated with ECMO, 
providing appropriate precautions and a very experienced team.
Implications for clinical practice
In summary, the most critical factor in managing the patient 
with ARDS is the initiation of lung-protective MV immediately 
upon intubation. In most patients with severe ARDS, a period 
of NMB agents with sedatives/narcotics is needed to gain stabil-
ity of the cardiovascular/respiratory systems that are maximally 
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stressed. Whether NMBs need to be administered for 48 hours in 
all patients is still open to debate, but some period from 8 to 48 
hours seems beneficial in patients with severe ARDS. Once patients 
are stabilized, the lung should be recruited and PEEP set by a 
decremental best compliance PEEP trial or by PEEP establish-
ing a positive end-expiratory transpulmonary pressure (both 
techniques resulting in the same PEEP). Once PEEP is set, VT 
is adjusted to 4 to 8 mL/kg PBW to maintain a driving pressure 
of less than 15 cm H2O and a plateau pressure of less than 30 cm 
H2O with ventilator rate increased to manage partial pressure of 
carbon dioxide in arterial blood (PaCO2). Finally, the FiO2 should 
be decreased to the lowest level that maintains the PaO2 of 55 to 
80 mm Hg and the SpO2 of 88% to 95%. In patients in whom 
persistent hypoxemia persists, prone positioning should be con-
sidered, and in those in whom refractory hypoxemia persists 
after proning, ECMO should be considered. Many of the above 
steps in managing severe ARDS are still considered controversial 
since they are supported only by single RCTs, non-RCTs, or 
retrospective analysis. However, until data from ongoing studies 
are available, this seems to be the most beneficial and unifying 
approach to the management of the patient with severe ARDS and 
persistent hypoxemia.
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